Delivery Order SPE2DB20D1109-SPE2DB25FP40S
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $25,169.28 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $6,391.17 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on June 26, 2025, with completion scheduled for June 27, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The company, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $55,018.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on June 18, 2025, with completion targeted for June 20, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $61,467.35 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 3, 2025, with a completion date of November 4, 2025. This non-competitive, firm fixed-price delivery order represents a single-source procurement under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The company, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $21,925.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order is non-competitive and carries no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location. The award represents a child order under...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $9,263.85 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with an ultimate completion date of July 15, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99 million...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP40SDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,671.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 16, 2025, with completion scheduled for July 17, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The pharmaceutical distributor will perform under this delivery order from its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical procurement through AmerisourceBergen's comprehensive global pharmaceutical support vehicle, which enables the company to supply brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare programs worldwide. Dupixent is a biologic medication commonly prescribed for conditions including moderate-to-severe atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps. As a major pharmaceutical distributor serving federal medical supply chains, AmerisourceBergen maintains significant capacity to fulfill such orders for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.7k | 7/16/25 |